Trials / Completed
CompletedNCT05406752
Pharmacokinetic Study of Paracetamol UNIFLASH (125 MG/1.25 ML)
An Open-label, Single Treatment, Single Period, Single Buccal Dose Pharmacokinetic Study of Paracetamol Uniflash (125 mg/ 1.25 mL) in Healthy, Adult, Human Subjects Under Fasting Conditions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Unither Pharmaceuticals, France · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study aims to assess the pharmacokinetic profile of a new paracetamol formulation (paracetamol Uniflash 125mg/1.25mL) for buccal use after single dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paracetamol Uniflash (125 mg/ 1.25 mL) | Oromucosal solution (125 mg/ 1.25 mL) for buccal route |
Timeline
- Start date
- 2022-07-22
- Primary completion
- 2022-07-23
- Completion
- 2022-07-23
- First posted
- 2022-06-06
- Last updated
- 2024-12-13
- Results posted
- 2024-12-13
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT05406752. Inclusion in this directory is not an endorsement.